T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Texas Instruments
TXN
|
+$2.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.81B |
| 3 |
Broadcom
AVGO
|
+$1.61B |
| 4 |
Tesla
TSLA
|
+$1.59B |
| 5 |
Sempra
SRE
|
+$1.26B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$6.14B |
| 2 |
Amazon
AMZN
|
+$2.54B |
| 3 |
AET
Aetna Inc
AET
|
+$1.44B |
| 4 |
Biogen
BIIB
|
+$1.4B |
| 5 |
Netflix
NFLX
|
+$1.12B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 16.61% |
| 2 | Healthcare | 16.14% |
| 3 | Financials | 15.97% |
| 4 | Consumer Discretionary | 14.71% |
| 5 | Industrials | 9.85% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MYOV
1326
DELISTED
Myovant Sciences Ltd.
MYOV
| $10.2M | ﹤0.01% |
478,609
+432,113
| +929% | +$6.58M |
|
1327
James River Group Holdings
JRVR
$200M
| $10.2M | ﹤0.01% |
286,938
+91,437
| +47% | +$3.33M |
|
1328
Copa Holdings
CPA
$6.17B
| $10.1M | ﹤0.01% |
78,710
+10,553
| +15% | +$1.42M |
|
1329
Arcus Biosciences
RCUS
$3.67B
| $10.1M | ﹤0.01% |
+655,438
| New | +$10.9M |
|
|
GRMN
1330
Garmin
GRMN
$60.2B
| $10.1M | ﹤0.01% |
171,279
+5,600
| +3% | +$343K |
|
1331
ON Semiconductor
ON
$31.8B
| $10.1M | ﹤0.01% |
411,636
-31,663
| -7% | -$764K |
|
1332
Leggett & Platt
LEG
$1.32B
| $9.88M | ﹤0.01% |
222,666
-5,400
| -2% | -$248K |
|
1333
H&R Block
HRB
$6.76B
| $9.85M | ﹤0.01% |
387,772
-2,800
| -0.7% | -$73.7K |
|
1334
Brinker International
EAT
$10.2B
| $9.83M | ﹤0.01% |
272,371
-107,910
| -28% | -$3.92M |
|
1335
Range Resources
RRC
$9.33B
| $9.73M | ﹤0.01% |
668,995
+35,700
| +6% | +$534K |
|
1336
Quanta Services
PWR
$101B
| $9.71M | ﹤0.01% |
282,780
-1,000
| -0.4% | -$36.3K |
|
1337
Roku
ROKU
$22.9B
| $9.66M | ﹤0.01% |
+310,657
| New | +$12.8M |
|
|
FL
1338
DELISTED
Foot Locker
FL
| $9.64M | ﹤0.01% |
211,638
-2,188
| -1% | -$102K |
|
1339
Synaptics
SYNA
$4.2B
| $9.63M | ﹤0.01% |
210,684
+268
| +0.1% | +$12.2K |
|
1340
Rigel Pharmaceuticals
RIGL
$762M
| $9.51M | ﹤0.01% |
268,576
+181
| +0.1% | +$7.25K |
|
|
JWN
1341
DELISTED
Nordstrom
JWN
| $9.48M | ﹤0.01% |
195,938
-5,100
| -3% | -$254K |
|
1342
Q32 Bio
QTTB
$458M
| $9.41M | ﹤0.01% |
+27,956
| New | +$9.4M |
|
1343
Fate Therapeutics
FATE
$294M
| $9.4M | ﹤0.01% |
962,773
+437,166
| +83% | +$4.19M |
|
|
GXP
1344
DELISTED
Great Plains Energy Incorporated
GXP
| $9.37M | ﹤0.01% |
294,757
+24,940
| +9% | +$760K |
|
1345
Forte Biosciences
FBRX
$1.57B
| $9.37M | ﹤0.01% |
2,108
-40
| -2% | -$185K |
|
|
KW
1346
DELISTED
Kennedy-Wilson Holdings
KW
| $9.33M | ﹤0.01% |
535,989
+4,254
| +0.8% | +$73K |
|
1347
Globant
GLOB
$1.77B
| $9.23M | ﹤0.01% |
179,182
-44,227
| -20% | -$2.17M |
|
1348
Ternium
TX
$10.7B
| $9.16M | ﹤0.01% |
282,076
+20,404
| +8% | +$691K |
|
1349
Rocket Pharmaceuticals
RCKT
$367M
| $9.09M | ﹤0.01% |
485,005
+240,930
| +99% | +$3.93M |
|
|
CBAY
1350
DELISTED
Cymabay Therapeutics
CBAY
| $9.09M | ﹤0.01% |
+700,100
| New | +$8.7M |
|
Similar funds
T. Rowe Price Associates's Q1 2018 Portfolio in Review
As of Q1 2018, T. Rowe Price Associates held 2,649 positions worth $629B, up 2.1% from $616B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
T. Rowe Price Associates's Q1 2018 filing shows 91 new, 1,526 increased, 842 reduced and 97 closed positions. Its largest new stake was Sempra Energy 6% Mandatory Convertible Preferred Stock, Series A: 6,723,426 shares worth $688M. The largest sale was Apple, an estimated $6.14B.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2018 buy was Sempra Energy 6% Mandatory Convertible Preferred Stock, Series A: 6,723,426 shares worth $688M.
- T. Rowe Price Associates added most to Texas Instruments in Q1 2018, an estimated $2.29B increase.
- T. Rowe Price Associates's biggest Q1 2018 reduction was Apple, cutting an estimated $6.14B.
- T. Rowe Price Associates fully exited Liberty Interactive Corporation Series A Liberty Ventures in Q1 2018, selling an estimated $395M.
- T. Rowe Price Associates's ten largest holdings make up 19% of its $629B portfolio in Q1 2018.
- T. Rowe Price Associates opened 91 new positions and closed 97 in Q1 2018.
- T. Rowe Price Associates's portfolio value rose 2.1% quarter-over-quarter to $629B.
Based on T. Rowe Price Associates's 13F filing for Q1 2018, filed 14 May 2018.